Data Sharing Statement

Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2015301.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	Gilead is committed to sharing clinical trial data with external medical experts and scientific researchers in the interest of advancing public health. As such, Gilead shares anonymized Individual Patient Data (IPD) upon request or as required by law and/or regulation. Qualified external researchers may request IPD for studies of Gilead compounds approved in the US and the EU with a marketing authorization date on or after January 1, 2014 and publicly listed on ClinicalTrials.gov or EU-CTR. For studies of newly approved compounds or indications the IPD will be available for request six months after FDA and EMA approval. Such requests are at Gilead's discretion and dependent on the nature of the request, the merit of the research proposed, availability of the data and the intended use of the data. If Gilead agrees to the release of clinical data for research purposes, the requestor will be required to sign a data sharing agreement (DSA) in order to ensure protection of patient confidentiality prior to the release of any data. Upon execution of the DSA, Gilead will provide access to patient-level clinical trial analysis datasets in a secured analysis environment. Gilead will also make available the CSR synopsis, protocol and statistical analysis plan (SAP).
Which data?	—
Additional information about data	Gilead Sciences shares anonymized individual patient data upon request or as required by law or regulation with qualified external researchers based on submitted curriculum vitae and reflecting non conflict of interest. The request proposal must also include a statistician. Approval of such requests is at

	Gilead Science's discretion and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data. Data requests should be sent to datarequest@gilead.com.
How or where can the data be obtained?	Data requests should be sent to datarequest@gilead.com.
When will data availability begin?	18 months after completion of trial
When will data availability end?	—
Will any supporting documents be available?	Yes
Which supporting documents?	Study protocol, statistical analysis plan, and clinical study report synopsis
Additional information about supporting documents	Documents will be redacted of any personal information or company confidential information.
How or where can supporting documents be obtained?	Documents will be shared through a secured Citrix environment. The protocol and SAP are also available at NEJM.org.
When will supporting documents availability begin?	The protocol and SAP are available immediately at NEJM.org. The CSR synopsis will be available when access to the secured Citrix environment is granted.
When will supporting documents availability end?	—
To whom will data be available?	Qualified external researchers
For what type of analysis or purpose?	—
By what mechanism?	—
Any other restrictions?	—
Additional information	—

This statement was posted on May 27, 2020, at NEJM.org.